https://www.biopharmawatch.com/news/AGL/agilon-health-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-05T20:05:00.000Z agilon health Sets Date to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VIR/vir-biotechnology-expanded-phase-2-results-hepatitis-delta BiopharmaWatch en 2026-10-05T20:05:00.000Z Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 https://www.biopharmawatch.com/news/NEO/neogenomics-executive-leadership-succession-plan BiopharmaWatch en 2026-10-05T20:05:00.000Z NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-cara-bauer-chief-people-officer BiopharmaWatch en 2026-10-05T20:05:00.000Z BioMarin Appoints Cara Bauer as Chief People Officer https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-presentation-kidney-week-2026 BiopharmaWatch en 2026-10-05T20:05:00.000Z Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting https://www.biopharmawatch.com/news/KRRO/korro-phase-1-2-trial-krro-121 BiopharmaWatch en 2026-10-05T20:05:00.000Z Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 https://www.biopharmawatch.com/news/LAB/standard-bi-tools-sells-microfluidics-business-archimed BiopharmaWatch en 2026-10-05T20:05:00.000Z Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q3-2026-financial-results BiopharmaWatch en 2026-10-05T20:05:00.000Z Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-bob-ragusa-board-appointment BiopharmaWatch en 2026-10-05T20:05:00.000Z Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-abstracts-liver-meeting-2026 BiopharmaWatch en 2026-10-05T20:05:00.000Z Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261005 BiopharmaWatch en 2026-10-05T20:02:00.000Z Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NGNE/neurogene-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261005 BiopharmaWatch en 2026-10-05T20:01:00.000Z Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GRAL/grail-new-data-nhs-galleri-pathfinder-2-edcc-esmo-2026 BiopharmaWatch en 2026-10-05T20:01:00.000Z GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-agreement-cancer-research-uk BiopharmaWatch en 2026-10-05T20:01:00.000Z ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development https://www.biopharmawatch.com/news/CABA/cabaletta-bio-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-05T20:01:00.000Z Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-proposed-public-offering-common-stock BiopharmaWatch en 2026-10-05T20:01:00.000Z Spyre Therapeutics Announces Proposed Public Offering of its Common Stock https://www.biopharmawatch.com/news/ABBV/abbvie-genmab-announce-epcoritamab-combination-r-chop-demonstrates-significant-improvement BiopharmaWatch en 2026-10-05T18:54:00.000Z AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/GMAB/genmab-abbvie-epcoritamab-r-chop-trial-results BiopharmaWatch en 2026-10-05T18:50:00.000Z Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/ABBV/epcoritamab-r-chop-dlbcl-trial-results BiopharmaWatch en 2026-10-05T18:49:00.000Z Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/AZN/astrazeneca-opens-new-rd-center-kendall-square BiopharmaWatch en 2026-10-05T16:01:00.000Z AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts https://www.biopharmawatch.com/news/HNGE/hinge-health-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-05T16:00:00.000Z Hinge Health to announce third quarter 2026 financial results on November 2, 2026 https://www.biopharmawatch.com/news/PRVA/anthem-blue-cross-privia-health-agreement-virginia BiopharmaWatch en 2026-10-05T15:49:00.000Z Anthem Blue Cross and Blue Shield in Virginia and Privia Health Reach New Agreement https://www.biopharmawatch.com/news/GH/guardant-health-cosmos-study-melanoma-recurrence BiopharmaWatch en 2026-10-05T15:27:00.000Z Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma https://www.biopharmawatch.com/news/AZN/serd-market-growth-2026-2036-astrazeneca-etcamah BiopharmaWatch en 2026-10-05T14:31:00.000Z SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-positive-phase-1a-data-abi-6250 BiopharmaWatch en 2026-10-05T14:00:00.000Z Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-antiviral-potential BiopharmaWatch en 2026-10-05T13:22:00.000Z AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential https://www.biopharmawatch.com/news/WAT/cellcarta-waters-partnership-companion-diagnostics BiopharmaWatch en 2026-10-05T13:15:00.000Z CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development https://www.biopharmawatch.com/news/PHG/philips-sonicare-diamondclean-9900-prestige-launch BiopharmaWatch en 2026-10-05T13:00:00.000Z Philips Sonicare Next-Generation DiamondClean 9900 Prestige Is Now Available On Amazon; The Brand’s Most Advanced, Intelligent Toothbrush That Gives Users Real-Time Guidance Alongside Signature Brushing Performance https://www.biopharmawatch.com/news/CVS/cvs-health-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-05T13:00:00.000Z CVS Health to hold third quarter 2026 earnings conference call https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-hope-3-deramiocel-data BiopharmaWatch en 2026-10-05T13:00:00.000Z Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress https://www.biopharmawatch.com/news/IMMX/immix-biopharma-jp-morgan-healthcare-conference-2027 BiopharmaWatch en 2026-10-05T12:45:00.000Z Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261005 BiopharmaWatch en 2026-10-05T12:32:00.000Z Novo Nordisk A/S – Share repurchase programme https://www.biopharmawatch.com/news/BEAT/heartbeam-fda-breakthrough-device-designation BiopharmaWatch en 2026-10-05T12:31:00.000Z HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-carlysle-trial-acr-convergence-2026 BiopharmaWatch en 2026-10-05T12:30:00.000Z Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 https://www.biopharmawatch.com/news/TMO/thermo-fisher-proteomics-discovery-precise-sg100k BiopharmaWatch en 2026-10-05T12:30:00.000Z Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-october-conferences BiopharmaWatch en 2026-10-05T12:30:00.000Z Aprea Therapeutics to Present at October Conferences https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261005 BiopharmaWatch en 2026-10-05T12:30:00.000Z Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-first-case-stable-disease-three-months-ovarian BiopharmaWatch en 2026-10-05T12:15:00.000Z Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial https://www.biopharmawatch.com/news/ARDX/ardelyx-new-data-hyperphosphatemia-asn-kidney-week-2026 BiopharmaWatch en 2026-10-05T12:01:00.000Z Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-3-rasolute-309-trial BiopharmaWatch en 2026-10-05T12:00:34.000Z Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer https://www.biopharmawatch.com/news/PCRX/pacira-molteni-agreement-exparel-eu-uk BiopharmaWatch en 2026-10-05T12:00:03.000Z Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom https://www.biopharmawatch.com/news/RANI/rani-therapeutics-fda-emerging-technology-program BiopharmaWatch en 2026-10-05T12:00:01.000Z Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) https://www.biopharmawatch.com/news/RADX/radiopharm-end-of-phase-2-fda-meeting-rad101 BiopharmaWatch en 2026-10-05T12:00:00.000Z Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101 https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-regulatory-update-bb-301 BiopharmaWatch en 2026-10-05T12:00:00.000Z Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study https://www.biopharmawatch.com/news/ESTA/establishment-labs-receives-fda-approval-additional-sizes-motiva-implants BiopharmaWatch en 2026-10-05T12:00:00.000Z Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants® https://www.biopharmawatch.com/news/ELV/elevance-health-conference-call-q3-2026-results BiopharmaWatch en 2026-10-05T12:00:00.000Z Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026 https://www.biopharmawatch.com/news/BFLY/butterfly-network-appoints-mike-noonen-board BiopharmaWatch en 2026-10-05T12:00:00.000Z Butterfly Network Appoints Mike Noonen to Board of Directors https://www.biopharmawatch.com/news/COYA/coya-therapeutics-phase-2-3-alstars-trial-completion BiopharmaWatch en 2026-10-05T12:00:00.000Z Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS https://www.biopharmawatch.com/news/GEHC/ge-healthcare-acquire-sofie-biosciences-pet-radiopharmaceuticals BiopharmaWatch en 2026-10-05T12:00:00.000Z GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S. https://www.biopharmawatch.com/news/NTRA/aft-70-navigate-global-randomized-phase-iii-trial BiopharmaWatch en 2026-10-05T12:00:00.000Z Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer https://www.biopharmawatch.com/news/ICU/seastar-medical-warrant-exercise-3-3-million BiopharmaWatch en 2026-10-05T12:00:00.000Z SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds https://www.biopharmawatch.com/news/FDMT/4dmt-investor-day-october-2026 BiopharmaWatch en 2026-10-05T12:00:00.000Z 4DMT to Host Investor Day on October 21, 2026 https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-appoints-matt-eckler-board BiopharmaWatch en 2026-10-05T12:00:00.000Z PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors https://www.biopharmawatch.com/news/CELC/celcuity-esmo-congress-2026-presentations BiopharmaWatch en 2026-10-05T12:00:00.000Z Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/LSTA/marea-therapeutics-phase-2-trial-mar002-acromegaly BiopharmaWatch en 2026-10-05T12:00:00.000Z Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-phase-3-catt1-study-completion BiopharmaWatch en 2026-10-05T12:00:00.000Z vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) https://www.biopharmawatch.com/news/TELA/tela-bio-510k-clearance-liora-scaffold BiopharmaWatch en 2026-10-05T12:00:00.000Z TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement https://www.biopharmawatch.com/news/HIND/vyome-usp-to-notice-allowance-vt-1908-patent BiopharmaWatch en 2026-10-05T12:00:00.000Z Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market https://www.biopharmawatch.com/news/PRME/prime-medicine-phase-1-2-trial-pm577a-wilson-disease BiopharmaWatch en 2026-10-05T11:59:59.000Z Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease https://www.biopharmawatch.com/news/LLY/lilly-dermatology-data-fall-clinical-2026 BiopharmaWatch en 2026-10-05T11:50:00.000Z Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-us-patent-dor-technology BiopharmaWatch en 2026-10-05T11:45:00.000Z TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology https://www.biopharmawatch.com/news/PLRZ/polyrizon-files-us-patent-intranasal-drug-delivery BiopharmaWatch en 2026-10-05T11:32:00.000Z Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform https://www.biopharmawatch.com/news/BBIO/bbp-418-potential-disease-modifying-therapy-lgmd2i-r9 BiopharmaWatch en 2026-10-05T11:30:00.000Z BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels https://www.biopharmawatch.com/news/BLCO/bausch-lomb-third-quarter-2026-results BiopharmaWatch en 2026-10-05T11:30:00.000Z Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-fda-clearance-ind-cr-002 BiopharmaWatch en 2026-10-05T11:30:00.000Z Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors https://www.biopharmawatch.com/news/MMED/minimed-smart-mdi-alerts-glucose-outcomes BiopharmaWatch en 2026-10-05T11:08:00.000Z Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes https://www.biopharmawatch.com/news/HLF/herbalife-maxim-growth-summit-october-14 BiopharmaWatch en 2026-10-05T11:05:00.000Z Herbalife to Participate in 1 on 1 Meetings at Maxim Growth Summit on October 14 https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-phase-2-data-multiple-system-atrophy BiopharmaWatch en 2026-10-05T11:05:00.000Z Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders https://www.biopharmawatch.com/news/IVVD/invivyd-inducement-grants-nasdaq-listing-rule BiopharmaWatch en 2026-10-05T11:01:00.000Z Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PBM/psyence-biomeds-ibogaine-manufacturing-partnership BiopharmaWatch en 2026-10-05T11:00:00.000Z Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine https://www.biopharmawatch.com/news/ALEC/alector-genentech-license-agreement-parkinsons-disease BiopharmaWatch en 2026-10-05T11:00:00.000Z Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases https://www.biopharmawatch.com/news/MSLE/satellos-granted-patent-for-forazapadin BiopharmaWatch en 2026-10-05T11:00:00.000Z Satellos Granted Composition of Matter Patent for Forazapadin https://www.biopharmawatch.com/news/BCRX/biocryst-scientific-advisory-board-formation BiopharmaWatch en 2026-10-05T11:00:00.000Z BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth https://www.biopharmawatch.com/news/SMMT/astrazeneca-completes-2-billion-investment-summit-therapeutics BiopharmaWatch en 2026-10-05T11:00:00.000Z AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-fda-meeting-zorevunersen-dravet-syndrome BiopharmaWatch en 2026-10-05T11:00:00.000Z Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome https://www.biopharmawatch.com/news/IRIX/iridex-relocation-manufacturing-facility-san-jose BiopharmaWatch en 2026-10-05T11:00:00.000Z Iridex Completes Relocation of Manufacturing Facility to San Jose, California https://www.biopharmawatch.com/news/RZLT/rezolute-fda-pre-bla-meeting-ersodetug BiopharmaWatch en 2026-10-05T11:00:00.000Z Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism https://www.biopharmawatch.com/news/HROW/harrow-acquires-tyrvaya-nasal-spray BiopharmaWatch en 2026-10-05T11:00:00.000Z Harrow Closes Acquisition of TYRVAYA® https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-research-term-extension-gilead BiopharmaWatch en 2026-10-05T11:00:00.000Z Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences https://www.biopharmawatch.com/news/VTRS/viatris-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-05T10:59:00.000Z Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/PHVS/real-world-analysis-hai-disease-experience-treatment-gaps BiopharmaWatch en 2026-10-05T10:50:27.000Z Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy https://www.biopharmawatch.com/news/CMPS/compass-pathways-new-office-jersey-city BiopharmaWatch en 2026-10-05T10:30:00.000Z Compass Pathways Celebrates Opening of New U.S. Office in Jersey City, New Jersey https://www.biopharmawatch.com/news/FTRE/fortrea-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-05T10:30:00.000Z Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call https://www.biopharmawatch.com/news/EW/edwards-lifesciences-host-investor-event-tct BiopharmaWatch en 2026-10-05T10:00:00.000Z Edwards Lifesciences to Host Investor Event in Conjunction With TCT https://www.biopharmawatch.com/news/WST/west-highlight-industry-leadership-cphi-worldwide BiopharmaWatch en 2026-10-05T10:00:00.000Z West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-1-phase-3-trial-results BiopharmaWatch en 2026-10-05T10:00:00.000Z Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate https://www.biopharmawatch.com/news/ALVO/fda-approves-additional-manufacturing-capacity-simlandi BiopharmaWatch en 2026-10-05T08:00:00.000Z FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® https://www.biopharmawatch.com/news/BMY/help-save-a-life-blood-donation-drive-bmy BiopharmaWatch en 2026-10-05T07:54:00.000Z Driving Community Health: Bristol Myers Squibb, Emirates Thalassemia Society and Dubai Science Park Host the 6th 'Help Save a Life' Blood Donation Drive https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-05 BiopharmaWatch en 2026-10-05T07:15:33.007Z SIL204 Phase 2/3 for Locally Advanced Pancreatic Cancer: Biotech Catalysts Oct 5, 2026 https://www.biopharmawatch.com/news/PCVX/vaxcyte-webcast-opus-1-phase-3-trial-data BiopharmaWatch en 2026-10-04T21:00:00.000Z Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-ovarian-cancer-bot-bal BiopharmaWatch en 2026-10-04T02:42:00.000Z Agenus informa una supervivencia estimada a tres años del 48 % con BOT+BAL para cáncer de ovarios recurrente en IGCS 2026 https://www.biopharmawatch.com/news/AGEN/riassunto-agenus-segnala-una-sopravvivenza-tre-anni-stimata-al-48 BiopharmaWatch en 2026-10-04T02:42:00.000Z Riassunto: Agenus segnala una sopravvivenza a tre anni stimata al 48% con BOT+BAL nel tumore ovarico recidivante all'IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-rate-ovarian-cancer BiopharmaWatch en 2026-10-04T02:41:00.000Z Samenvatting: Agenus rapporteert een geschatte driejarige overleving van 48% met BOT+BAL bij recidiverende eierstokkanker tijdens IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-dreijahresueberlebensrate-eierstockkrebs BiopharmaWatch en 2026-10-04T02:40:00.000Z Agenus meldet auf der IGCS 2026 eine geschätzte Dreijahresüberlebensrate von 48 % mit BOT+BAL bei rezidivierendem Eierstockkrebs